Update on Biological Therapies for Critical Limb Ischemia

Cardiology Clinics

Volumn 29, Issue 3, 2011, Pages 411-417

  Powell, Richard J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Biological therapy; Critical limb ischemia; Gene; Stem cell

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; SCATTER FACTOR; VASCULOTROPIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENIC GENE THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CLAUDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LIMB AMPUTATION; LIMB ISCHEMIA; NEOPLASM; PAIN; PRIORITY JOURNAL; RETINOPATHY; REVIEW; ULCER; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING;

BIOLOGICAL THERAPY; EXTREMITIES; GENE THERAPY; HUMANS; ISCHEMIA; LIMB SALVAGE; PERIPHERAL ARTERIAL DISEASE; STEM CELL TRANSPLANTATION;

EID: 79960772711     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2011.05.001     Document Type: Review

References (30)

1. Adam D.J., Beard J.D., Cleveland T., et al. BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366:1925-1934.
2. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in subjects with peripheral arterial disease. N Engl J Med 1992, 326:381-386.
3. Dormandy J.A., Heeck L., Vig S. The fate of subjects with critical leg ischemia. Semin Vasc Surg 1999, 12:142-147.
4. Marston W.A., Davies S.W., Armstrong B., et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg 2006, 44:108-114.
5. Brass E.P., Anthony R., Dormandy J., et al. Intensive parenteral therapy with lipo-ecraprost, a lipid-based formulation of a prostaglandin E1 analog does not alter six-month outcomes in patients with critical leg ischemia who are not candidates for revascularization. J Vasc Surg 2006, 43:752-759.
6. Nehler M.R., Brass E.P., Anthony R., Circulase investigators, et al. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg 2007, 45:953-961.
7. Powell R.J., Goodney P., Mendelsohn F.O., et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010, 52:1525-1530.
8. Conte M.S., Geraghty P.J., Bradbury A.W., et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009, 50(6):1462-1473.
9. Norgren L., Hiatt W.R., Dormandy J., et al. Trans-Atlantic inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl 1):s1-s75.
10. Hiatt W. Results of NV1FGF gene therapy on amputation-free survival in critical limb ischemia - phase 3 randomized double-blind placebo-controlled trial. Paper presented at: 2010 American Heart Association Scientific Sessions. Chicago (IL), 2010.
11. Powell R.J., Simons M., Mendelsohn F.O., et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008, 118:58-65.
12. Conte M., Bandyk D., Clowes A., et al. Risk factors, medical therapies and peri-operative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005, 42:456-465.
13. Giles K.A., Pomposelli F.B., Hamdan A.D., et al. Infrapopliteal angioplasty for critical limb ischemia: relation of transAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg 2008, 48:128-136.
14. Lederman R.J., Mendelsohn F.O., Anderson R.D., TRAFFIC Investigators, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: the TRAFFIC study. Lancet 2002, 359:2053-2058.
15. Mohler E.R., Rajagopalan S., Olin J.W., et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc Med 2003, 8(1):9-13.
16. Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
17. Isner J.M., Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
18. Rajagopalan S., Olin J., Deitcher S., et al. Use of a constitutively active hypoxia-inducible factor-1a transgene as a therapeutic strategy in no-option critical limb ischemia patients. Circulation 2007, 115:1234-1243.
19. Baumgartner I., Chronos N., Camerota A., et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009, 17:914-921.
20. Comerota A.J., Throm R.C., Miller K.A., et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002, 35:930-936.
21. Nikol S., Baumgartner I., Van Belle E., et al. Therapeutic angiogenesis with intramuscular NV1FGF improved amputation-free survival in patients with critical limb ischemia. Mol Ther 2008, 16:972-978.
22. Shigematsu H., Yasuda K., Iwai T., et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010, 17(9):1152-1161.
23. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85:221-228.
24. Amann B., Luedemann C., Ratei R., et al. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant 2009, 18:371-380.
25. Sprengers R.W., Moll F.L., Teraa M., et al. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg 2010, 51:1564-1568.
26. Lawall H., Bramlage P., Aman B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011, 53:445-453.
27. Lafrati M., Bandyk D., Benoit E., et al. Bone marrow aspirate concentrate in critical limb ischemia: results of a multicenter randomized double blind trial. J Vasc Surg 2010, 52:11.
28. Powell R. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multi-center phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. Presented at Society for Vascular Surgery Annual Meeting. June, 2010.
29. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 2002, 360:427-435.
30. Conte M., Bandyk D., Clowes A., et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006, 43:742-751.